|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TARM1 |
Gene summary for TARM1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TARM1 | Gene ID | 441864 |
| Gene name | T cell-interacting, activating receptor on myeloid cells 1 | |
| Gene Alias | OLT-2 | |
| Cytomap | 19q13.42 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | B6A8C7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 441864 | TARM1 | HCC1 | Human | Liver | HCC | 3.12e-03 | 5.23e-01 | 0.5336 |
| 441864 | TARM1 | HCC2 | Human | Liver | HCC | 5.11e-07 | 8.40e-01 | 0.5341 |
| 441864 | TARM1 | HCC5 | Human | Liver | HCC | 4.66e-09 | 7.54e-01 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Esophagus | ESCC |  |
| Skin | AK |  |
| Skin | SCCIS |  |
| Skin | cSCC |  |
| Thyroid | HT |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TARM1 | insertion | Frame_Shift_Ins | novel | c.413_414insT | p.Tyr139LeufsTer82 | p.Y139Lfs*82 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| TARM1 | insertion | In_Frame_Ins | novel | c.412_413insAAACAAAAAACAAAAACAAAAACAACAAAACAACAAAAAAAC | p.Thr138delinsLysThrLysAsnLysAsnLysAsnAsnLysThrThrLysLysPro | p.T138delinsKTKNKNKNNKTTKKP | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| TARM1 | SNV | Missense_Mutation | rs774762868 | c.355N>T | p.His119Tyr | p.H119Y | protein_coding | deleterious(0.04) | benign(0.14) | TCGA-AA-A02O-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TARM1 | SNV | Missense_Mutation | c.262N>A | p.Ala88Thr | p.A88T | protein_coding | deleterious(0.02) | possibly_damaging(0.858) | TCGA-DM-A28F-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| TARM1 | SNV | Missense_Mutation | c.758T>C | p.Val253Ala | p.V253A | protein_coding | deleterious(0.03) | benign(0.081) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD | ||
| TARM1 | SNV | Missense_Mutation | rs2361558 | c.265G>A | p.Glu89Lys | p.E89K | protein_coding | tolerated(0.17) | benign(0.019) | TCGA-AJ-A5DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TARM1 | SNV | Missense_Mutation | novel | c.496N>C | p.Phe166Leu | p.F166L | protein_coding | deleterious(0.03) | possibly_damaging(0.46) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TARM1 | SNV | Missense_Mutation | novel | c.569N>A | p.Ser190Tyr | p.S190Y | protein_coding | tolerated(0.08) | benign(0.299) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | |
| TARM1 | SNV | Missense_Mutation | rs766519782 | c.683N>C | p.Val228Ala | p.V228A | protein_coding | tolerated(1) | benign(0.189) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| TARM1 | SNV | Missense_Mutation | novel | c.341A>G | p.His114Arg | p.H114R | protein_coding | tolerated(0.22) | benign(0) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |